Predicted efficacy of a pharmacogenetic passport for inflammatory bowel disease
Open Access
- 3 May 2020
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 51 (11), 1105-1115
- https://doi.org/10.1111/apt.15762
Abstract
Background High inter‐individual variability in therapeutic response to drugs used in the management of Inflammatory Bowel Disease (IBD) leads to high morbidity and high costs. Genetic variants predictive of thiopurine‐induced myelosuppression, thiopurine‐induced pancreatitis and immunogenicity of Tumour Necrosis Factor alpha (TNFα) antagonists have been identified, but uptake of pre‐treatment pharmacogenetic testing into clinical guidelines has been slow. Aim To explore the efficacy of a pharmacogenetic passport for IBD that includes multiple pharmacogenetic predictors of response. Methods Patients with IBD exposed to thiopurines and/or TNFα antagonists were retrospectively evaluated for the presence of thiopurine toxicity and/or immunogenicity of TNFα antagonists. All patients were genotyped using both whole‐exome sequencing and the Illumina Global Screening Array. An in‐house‐developed computational pipeline translated genetic data into an IBD pharmacogenetic passport that predicted risks for thiopurine toxicity and immunogenicity of TNFα antagonists per patient. Using pharmacogenetic‐guided treatment guidelines, we calculated clinical efficacy estimates for pharmacogenetic testing for IBD. Results Among 710 patients with IBD exposed to thiopurines and/or TNFα antagonists, 150 adverse drug responses occurred and our pharmacogenetic passport would have predicted 54 (36%) of these. Using a pharmacogenetic passport for IBD that includes genetic variants predictive of thiopurine‐induced myelosuppression, thiopurine‐induced pancreatitis, and immunogenicity of TNFα antagonists, 24 patients need to be genotyped to prevent one of these adverse drug responses. Conclusions This study highlights the clinical efficacy of a pharmacogenetic passport for IBD. Implementation of such a pharmacogenetic passport into clinical management of IBD may contribute to a reduction in adverse drug responses.Funding Information
- Maag Lever Darm Stichting (CDG 14-04, D16-14)
This publication has 34 references indexed in Scilit:
- HLA-DQA1–HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressantsNature Genetics, 2014
- Safety of Thiopurine Therapy in Inflammatory Bowel DiseaseInflammatory Bowel Diseases, 2013
- Detection of infliximab levels and anti‐infliximab antibodies: a comparison of three different assaysAlimentary Pharmacology & Therapeutics, 2012
- Development and Inter-Rater Reliability of the Liverpool Adverse Drug Reaction Causality Assessment ToolPLOS ONE, 2011
- Guidelines for the management of inflammatory bowel disease in adultsGut, 2011
- A novel method for the detection of antibodies to adalimumab in the presence of drug reveals “hidden” immunogenicity in rheumatoid arthritis patientsJournal of Immunological Methods, 2010
- The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing dataGenome Research, 2010
- Principal components analysis corrects for stratification in genome-wide association studiesNature Genetics, 2006
- Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritisArthritis & Rheumatism, 2006
- Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel diseasePharmacoepidemiology and Drug Safety, 2004